The Immune Modulatory Function Of Chondroitin Sulphate A In Placental Malaria: Protecting The Fetus, Promoting The Parasite?
Funder
National Health and Medical Research Council
Funding Amount
$529,206.00
Summary
Pregnant women and their babies are susceptible to placental malaria infection. Malaria parasites infect the placenta by binding to chondroitin sulfate A (CSA). CSA levels increase in normal pregnancy. Studies suggest that CSA can suppress immune cell function. This study will look at the immune modulating function of CSA during pregnancy and placental malaria. CSA may act as camouflage, hiding the malaria parasite from immune cells. This may be a novel immune evasion pathway.
How Do Bone-active Drugs Increase Patient Survival?
Funder
National Health and Medical Research Council
Funding Amount
$613,952.00
Summary
Bisphosphonates are a class of drugs used to prevent bone destruction in diseases such as osteoporosis. Evidence is emerging that these drugs also act on cells outside the skeleton to have additional beneficial effects, for example prolonging patient survival. This project will identify the cells affected and the mechanisms involved. With this knowledge, these drugs could be used more effectively and in different ways for the prevention or treatment of cancer and chronic human illnesses.
Deciphering The Role Of Intron Retention In Monocyte Differentiation And Function
Funder
National Health and Medical Research Council
Funding Amount
$511,114.00
Summary
In 2013, we made a breakthrough discovery that certain parts of genes, previously considered “Junk DNA”, are actually carrying signals to control the amount of proteins produced in cells. We now wish to understand the roles of these signals in the development of a key immune cell called monocyte. Monocytes are important to fight infection and inflammation in diseases such as diabetes and cancer. We hope to advance our knowledge on how we can manipulate these cells for therapeutic gain.
Targetting Monocytes With Microparticles To Prevent Kidney Allograft Rejection
Funder
National Health and Medical Research Council
Funding Amount
$967,005.00
Summary
Whilst transplantation is lifesaving for many Australians with organ failure, it is a treatment rather than cure as recipients are dependent upon lifelong immunosuppression to prevent transplant rejection. Risks of death due to infection and cancer therefore remain high. We will test a new strategy in mice which modifies recipients of monocytes at the time of transplantation, to enable them to accept and tolerate the organ without ongoing need for expensive and dangerous immunosuppressive drugs.
Immune-modifying-particle-induced Tregs Induce Remission In Experimental Autoimmune Encephalomyelitis
Funder
National Health and Medical Research Council
Funding Amount
$512,440.00
Summary
Multiple Sclerosis is a debilitating autoimmune disease of the central nervous system. Disease is the result of inflammatory monocyte-derived dendritic cells that migrate from the blood into the brain, where they stimulate T cells to attack myelin sheaths around neurons. Our novel therapy, known as immune modulating micro-particles reduces monocyte migration and disease in a mouse model, we hypothesize, by inducing immunosuppressive T regulatory cells that control attacking T cells in MS.
A New Monocyte Atherogenic Phenotype In Chronic HIV Disease.
Funder
National Health and Medical Research Council
Funding Amount
$632,037.00
Summary
Most HIV+ people in Australia now die from cardiovascular disease, caused by atherosclerosis or thickening of coronary arteries. The ability of a white blood cell called the monocyte to prevent atherosclerosis is impaired in HIV. This project aims to understand how HIV does this and how we can reverse the effect. Understanding these processes will also help improve treatments to reduce heart disease in people with other chronic inflammatory conditions.